BDSX vs. PSNL, SERA, ENZ, RNLX, XGN, DMTK, CNTG, CELC, CSTL, and FLGT
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Personalis (PSNL), Sera Prognostics (SERA), Enzo Biochem (ENZ), Renalytix (RNLX), Exagen (XGN), DermTech (DMTK), Centogene (CNTG), Celcuity (CELC), Castle Biosciences (CSTL), and Fulgent Genetics (FLGT). These companies are all part of the "medical laboratories" industry.
Personalis (NASDAQ:PSNL) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.
Biodesix has a net margin of -85.80% compared to Biodesix's net margin of -124.89%. Biodesix's return on equity of -58.31% beat Personalis' return on equity.
Personalis has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.
In the previous week, Biodesix had 7 more articles in the media than Personalis. MarketBeat recorded 13 mentions for Biodesix and 6 mentions for Personalis. Biodesix's average media sentiment score of 1.04 beat Personalis' score of 0.67 indicating that Personalis is being referred to more favorably in the media.
Biodesix has lower revenue, but higher earnings than Personalis. Biodesix is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.
Personalis received 83 more outperform votes than Biodesix when rated by MarketBeat users. However, 72.97% of users gave Biodesix an outperform vote while only 65.48% of users gave Personalis an outperform vote.
Personalis presently has a consensus price target of $5.00, indicating a potential upside of 259.71%. Biodesix has a consensus price target of $3.10, indicating a potential upside of 96.20%. Given Biodesix's higher probable upside, analysts plainly believe Personalis is more favorable than Biodesix.
61.9% of Personalis shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 4.1% of Personalis shares are owned by company insiders. Comparatively, 63.8% of Biodesix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Personalis beats Biodesix on 9 of the 17 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
